Nyxoah SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: BE0974358906
EUR
4.12
-2.84 (-40.82%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

51.49 k

Shareholding (Dec 2023)

FII

12.17%

Held by 42 FIIs

DII

86.77%

Held by 1 DIIs

Promoter

0.61%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Operating profit has grown by an annual rate -186.94% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -27.33
2

Flat results in Dec 20

3

Risky -

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 151 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.71

stock-summary
Return on Equity

-167.66%

stock-summary
Price to Book

2.96

Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Jun 2025)
Net Profit:
-21 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-54.47%
0%
-54.47%
6 Months
-44.41%
0%
-44.41%
1 Year
-50.06%
0%
-50.06%
2 Years
-45.0%
0%
-45.0%
3 Years
-69.35%
0%
-69.35%
4 Years
-82.03%
0%
-82.03%
5 Years
0%
0%
0.0%

Nyxoah SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
41.75%
EBIT Growth (5y)
-186.94%
EBIT to Interest (avg)
-27.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.47
Sales to Capital Employed (avg)
1.08
Tax Ratio
4.97%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.99%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.37
EV to EBIT
-2.03
EV to EBITDA
-2.11
EV to Capital Employed
2.99
EV to Sales
30.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-147.37%
ROE (Latest)
-106.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.46%)

Foreign Institutions

Held by 42 Foreign Institutions (12.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 62.50% vs -27.27% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -57.25% vs -2.34% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.30",
          "val2": "0.80",
          "chgp": "62.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.10",
          "val2": "-12.70",
          "chgp": "-50.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.60",
          "val2": "-13.10",
          "chgp": "-57.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-14,836.60%",
          "val2": "-17,334.60%",
          "chgp": "249.80%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.65% vs 38.71% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -37.04% vs -38.46% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.50",
          "val2": "4.30",
          "chgp": "4.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-57.10",
          "val2": "-43.30",
          "chgp": "-31.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.20",
          "chgp": "58.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.40",
          "val2": "-0.10",
          "chgp": "-300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.20",
          "val2": "-43.20",
          "chgp": "-37.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,230.90%",
          "val2": "-10,498.20%",
          "chgp": "-273.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.30
0.80
62.50%
Operating Profit (PBDIT) excl Other Income
-19.10
-12.70
-50.39%
Interest
0.40
0.10
300.00%
Exceptional Items
0.20
0.00
Consolidate Net Profit
-20.60
-13.10
-57.25%
Operating Profit Margin (Excl OI)
-14,836.60%
-17,334.60%
249.80%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 62.50% vs -27.27% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -57.25% vs -2.34% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4.50
4.30
4.65%
Operating Profit (PBDIT) excl Other Income
-57.10
-43.30
-31.87%
Interest
1.90
1.20
58.33%
Exceptional Items
-0.40
-0.10
-300.00%
Consolidate Net Profit
-59.20
-43.20
-37.04%
Operating Profit Margin (Excl OI)
-13,230.90%
-10,498.20%
-273.27%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 4.65% vs 38.71% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -37.04% vs -38.46% in Dec 2023

stock-summaryCompany CV
About Nyxoah SA stock-summary
stock-summary
Nyxoah SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available